Pycnogenol® in Metabolic Syndrome and Related Disorders

Phytotherapy Research

Volumn 29, Issue 7, 2015, Pages 949-968

  Gulati, Om P ^a  

^a Horphag Research   (Switzerland)

Author keywords

clinical research; diabetes; dyslipidaemia; food supplement; hypertension; metabolic syndrome; obesity; Pycnogenol ; renal dysfunction

Indexed keywords

ALPHA GLUCOSIDASE; AUTACOID; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; LIPID; NIFEDIPINE; NITRIC OXIDE; PLACEBO; PYCNOGENOL; RAMIPRIL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ENDOTHELIUM DERIVED RELAXING FACTOR; FLAVONOID; GLUCOSE BLOOD LEVEL; PLANT EXTRACT; PYCNOGENOLS; VASODILATOR AGENT;

ADRENERGIC SYSTEM; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTITHROMBOTIC ACTIVITY; BLOOD PRESSURE REGULATION; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ECZEMA; EMOTIONAL STRESS; ENDOTHELIUM; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GENOTYPE ENVIRONMENT INTERACTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; MOUTH ULCER; MULTICENTER STUDY (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PINE; PINUS PINASTER; POSTMARKETING SURVEILLANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SEDATION; SEDENTARY LIFESTYLE; SIDE EFFECT; SOMNOLENCE; THROMBOCYTE FUNCTION; TISSUE BLOOD FLOW; TREATMENT DURATION; URTICARIA; VASODILATATION; VERTIGO; WAIST CIRCUMFERENCE; BARK; BLOOD PRESSURE; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DYSLIPIDEMIAS;

PINUS PINASTER;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BLOOD GLUCOSE; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; DYSLIPIDEMIAS; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; FLAVONOIDS; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; PINUS; PLANT BARK; PLANT EXTRACTS; VASODILATOR AGENTS; WAIST CIRCUMFERENCE;

EID: 84936882497     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5341     Document Type: Review

References (130)

1. Alberti KG, Zimmet PZ,. 1998. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553.
2. Alberti KG, Zimmet P, Shaw J, Group IDFETFC. 2005. The metabolic syndrome-a new worldwide definition. Lancet 366: 1059-1062.
3. Alberti KG, Eckel RH, Grundy SM, et al., 2009. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645.
4. Alonso D, Radomski MW,. 2003. The nitric oxide-endothelin-1 connection. Heart Fail Rev 8: 107-115.
5. Ando K, Fujita T,. 2009. Metabolic syndrome and oxidative stress. Free Radic Biol Med 47: 213-218.
6. Araghi-Niknam M, Hosseini S, Larson D, Rohdewald P, Watson RR,. 1999. Pine bark extract reduces platelet aggregation. Integr Med 2: 73-77.
7. Atkins RC, Briganti EM, Zimmet PZ, Chadban SJ,. 2003. Association between albuminuria and proteinuria in the general population: the AusDiab Study. Nephrol Dial Transplant 18: 2170-2174.
8. Belcaro G, Cesarone MR, Errichi BM, et al., 2005. Venous ulcers: microcirculatory improvement and faster healing with local use of Pycnogenol. Angiology 56: 699-705.
9. Belcaro G, Cesarone MR, Ricci A, et al., 2006. Control of edema in hypertensive subjects treated with calcium antagonist (nifedipine) or angiotensin-converting enzyme inhibitors with Pycnogenol. Clin Appl Thromb Hemost 12: 440-444.
10. Belcaro G, Cornelli U, Luzzi R, et al., 2013. Pycnogenol(R) supplementation improves health risk factors in subjects with metabolic syndrome. Phytother Res 27: 1572-1578.
11. Blazso G, Gabor M, Sibbel R, Rohdewald P,. 1994. Anti-inflammatory and superoxide radical scavenging activities of procyanidins containing extract from the bark of Pinus pinaster sol. and its fractions. Pharm Pharmacol Lett 3: 217-220.
12. Blazso G, Rohdewald P, Sibbel R, Gabor M,. 1995. Anti-inflammatory activities of procyanidin-containing extracts from Pinus pinaster sol. In Proceedings of the International Bioflavonoid Symposium, Antus S, Gabor M, Vetschera K, (eds.). Vienna, Austria
13. Blazso G, Gabor M, Rohdewald P,. 1997. Antiinflammatory activities of procyanidin-containing extracts from Pinus pinaster Ait. after oral and cutaneous application. Pharmazie 52: 380-382.
14. Blazso G, Gabor M, Schonlau F, Rohdewald P,. 2004. Pycnogenol accelerates wound healing and reduces scar formation. Phytother Res 18: 579-581.
15. Blumenthal M,. 2003. Pycnogenol (french maritime pine bark extract) pinus pinaster aiton subsp. Atlantica. In The American Botanical Council guide to Herbs, ABC: Austin, Texas USA; 369-373.
16. Borzelleca JF, Burdock GA, Thomas JA,. 2003. Opinion of an expert panel on the Generally Recognized As Safe (GRAS) status of French maritime pine bark extraxt (Pycnogenol(R)) as a flavoring agent. Internal document.
17. Cai H, Harrison DG,. 2000. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87: 840-844.
18. Cain AE, Khalil RA,. 2002. Pathophysiology of essential hypertension: role of the pump, the vessel, and the kidney. Semin Nephrol 22: 3-16.
19. Carretero OA, Gulati OP,. 1978. Effects of angiotensen antagonist in rats with acute, subacute, and chronic two-kidney renal hypertension. J Lab Clin Med 91: 264-271.
20. Carretero OA, Oparil S,. 2000a. Essential hypertension: part II: treatment. Circulation 101: 446-453.
21. Carretero OA, Oparil S,. 2000b. Essential hypertension: Part I: definition and etiology. Circulation 101: 329-335.
22. Ceriello A,. 2008. Possible role of oxidative stress in the pathogenesis of hypertension. Diabetes Care 31 (Suppl 2): S181-S184.
23. Cesarone MR, Belcaro G, Stuard S, et al., 2008a. Kidney flow and function in hypertension: protective effects of pycnogenol in hypertensive participants - a controlled study. J Cardiovasc Pharmacol Ther 15: 41-46.
24. Cesarone MR, Di Renzo A, Errichi S, Schonlau F, Wilmer JL, Blumenfeld J,. 2008b. Improvement in circulation and in cardiovascular risk factors with a proprietary isotonic bioflavonoid formula OPC-3. Angiology 59: 408-414.
25. Cesarone MR, Belcaro G, Stuard S, et al., 2010. Kidney flow and function in hypertension: protective effects of pycnogenol in hypertensive participants - a controlled study. J Cardiovasc Pharmacol Ther 15: 41-46.
26. Chen J, Muntner P, Hamm LL, et al., 2004. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140: 167-174.
27. Cho KJ, Yun CH, Packer L, Chung AS,. 2001. Inhibition mechanisms of bioflavonoids extracted from the bark of Pinus maritima on the expression of proinflammatory cytokines. Ann N Y Acad Sci 928: 141-156.
28. Cornier MA, Dabelea D, Hernandez TL, et al., 2008. The metabolic syndrome. Endocr Rev 29: 777-822.
29. Costa B, Barrio F, Cabre JJ, et al., 2012. Delaying progression to type 2 diabetes among high-risk Spanish individuals is feasible in real-life primary healthcare settings using intensive lifestyle intervention. Diabetologia 55: 1319-1328.
30. Dedoussis GV, Kaliora AC, Panagiotakos DB,. 2007. Genes, diet and type 2 diabetes mellitus: a review. Rev Diabet Stud 4: 13-24.
31. Devaraj S, Vega-Lopez S, Kaul N, Schonlau F, Rohdewald P, Jialal I,. 2002. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids 37: 931-934.
32. Drehsen G, 1999. From ancient pine bark uses to Pycnogenol. In Antioxidant Food Supplements in human health, Packer L, Hiramatsu M, Yoshikawa T, (eds.). Academic Press: New York, USA; 311-322.
33. Ò, extract from the bark of Pinus pinaster in patients suffering from erectile dysfunction- a pilot study. Nutr Res 23: 1189-1198.
34. Enseleit F, Sudano I, Périat D, et al., 2012. Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. http://www.ncbi.nlm.nih.gov/pubmed/22240497 Eur Heart J. 33 (13): 1589-1597.
35. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM,. 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42-47.
36. Fitzpatrick DF, Bing B, Rohdewald P,. 1998. Endothelium-dependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol 32: 509-515.
37. Gerich JE,. 1998. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 19: 491-503.
38. Ginsberg HN,. 2003. Treatment for patients with the metabolic syndrome. Am J Cardiol 91: 29E-39E.
39. Ginsberg HN, Huang LS,. 2000. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 7: 325-331.
40. Ginsberg HN, Stalenhoef AF,. 2003. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk. J Cardiovasc Risk 10: 121-128.
41. Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G,. 2008. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem 19: 491-504.
42. Grimm T, Schafer A, Hogger P,. 2004. Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (pycnogenol). Free Radic Biol Med 36: 811-822.
43. Grundy SM, Brewer HB Jr, Cleeman JI, et al., 2004a. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 24: e13-e18.
44. Grundy SM, Hansen B, Smith SC Jr, et al., 2004b. Clinical management of metabolic syndrome: report of the american heart association/national heart, lung, and blood institute/american diabetes association conference on scientific issues related to management. Circulation 109: 551-556.
45. Gulati OP,. 1999. Pycnogenol® in venous disorders: A review. Eur Bull Drug Res 7: 8-13.
46. Gulati OP,. 2005. The Nutraceutical Pycnogenol: its role in cardiovascular health and blood glucose control. Biomed Rev 16: 49-57.
47. Gulati OP,. 2008. Pycnogenol®-a nutraceutical for venous health. Biomed Rev 19: 33-43.
48. Gulati OP,. 2014. Pycnogenol(R) in chronic venous insufficiency and related venous disorders. Phytother Res 28: 348-362.
49. Gulati OP, Gulati N,. 1980. Effects of labetalol in chronic two-kidney Goldblatt hypertension (2-KGH) in rats. Arch Int Pharmacodyn Ther 243: 255-260.
50. Gulati OP, Liard JF,. 1979. Effects of propranolol in chronic two-kidney Goldblatt hypertension in rats. Arch Int Pharmacodyn Ther 240: 285-293.
51. Gulati OP, Chakravarti RN, Sharma PL,. 1974a. Experimental renal hypertension in rhesus monkeys: effect of surgical removal of ischaemic kidney on various parameters. Indian J Med Res 62: 736-744.
52. Gulati OP, Chakravarti RN, Sharma PL,. 1974b. Serial study of plasma angiotensin, electrolytes and juxta-glomerular index in experimental renal hypertension of monkeys. Indian J Med Res 62: 86-92.
53. Gulati OP, Carretero OA, Oza NB, Fernandez LA, Schork A,. 1975. Role of renin in the pathogenesis of renal hypertension. Circ Res 36: 187-193.
54. Gulati OP, Carretero OA, Morino T, Oza NB,. 1976. Urinary kallikrein and plasma renin during the reversal of renovascular hypertension in rats. Clin Sci Mol Med 3 (Suppl 3): 263s-266s.
55. Gulati OP, Chakravarti RN, Sharma PL,. 1978. Comparative effect of spironolactone and hydrochlorothiazide therapy in experimental renal hypertension of Rhesus monkeys. Indian J Med Res 67: 622-631.
56. Gulati N, Huggel H, Gulati OP,. 1982. Effects of captopril (SQ 14225) on norepinephrine-induced vasoconstriction in the isolated perfused mesentery and hindquarters of the rat. Arch Int Pharmacodyn Ther 255: 168-176.
57. Gulati N, Huggel H, Gulati OP,. 1984. Enalpril (MK-421) induced attenuation of norepinephrine induced responses in isolated perfused rat mesentery. Indian J Exp Biol 22: 57-58.
58. Gurevich-Panigrahi T, Panigrahi S, Wiechec E, Los M,. 2009. Obesity: pathophysiology and clinical management. Curr Med Chem 16: 506-521.
59. Haynes WG, Webb DJ,. 1998. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16: 1081-1098.
60. Heacock PM, Hertzler SR, Williams JA, Wolf BW,. 2005. Effects of a medical food containing an herbal alpha-glucosidase inhibitor on postprandial glycemia and insulinemia in healthy adults. J Am Diet Assoc 105: 65-71.
61. Hofbauer KG, Wood JM, Gulati N, Heusser C, Menard J,. 1985. Increased plasma renin during renin inhibition. Studies with a novel immunoassay. Hypertension 7: I61-I65.
62. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S,. 1993. Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett 334: 170-174.
63. Hosseini S, Lee J, Sepulveda RT, Rohdewald P, Watson RR,. 2001. A randomized, double-blind, placebo-controlled, prospective, 16week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutr Res 21: 1251-1260.
64. Hotta K, Funahashi T, Arita Y, et al., 2000. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599.
65. Howell SJ, Sear JW, Foex P,. 2004. Hypertension, hypertensive heart disease and perioperative cardiac risk. Br J Anaesth 92: 570-583.
66. Jastrzebska M, Przybycien K, Chelstowski K, Torbus-Lisiecka B, Kornacewicz-Jach Z, Naruszewicz M,. 1999. Increased levels of factor VII, fibrinogen and activity of plasminogen activator inhibitor during postprandial triglyceridemia in patients with ischemic heart disease confirmed by angiography. Nutr Metab Cardiovasc Dis 9: 33-40.
67. Jeong HS, Hong SJ, Lee TB, et al., 2014. Effects of black raspberry on lipid profiles and vascular endothelial function in patients with metabolic syndrome. Phytother Res 28: 1492-1498.
68. Kahn SE,. 2003. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46: 3-19.
69. Kahn CR, Vicent D, Doria A,. 1996. Genetics of non-insulin-dependent (type-II) diabetes mellitus. Annu Rev Med 47: 509-531.
70. Kim JCJ, Pinnas JL, Mooradian AD,. 2000. Effect of selected antioxidants on malondialdehyde modification of proteins. Nutrition 16: 1079-1081.
71. Kim YM, Jeong YK, Wang MH, Lee WY, Rhee HI,. 2005. Inhibitory effect of pine extract on alpha-glucosidase activity and postprandial hyperglycemia. Nutrition 21: 756-761.
72. King GL,. 2008. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 79: 1527-1534.
73. Kohama T, Suzuki N, Ohno S, Inoue M,. 2004. Analgesic efficacy of French maritime pine bark extract in dysmenorrhea: an open clinical trial. J Reprod Med 49: 828-832.
74. Kowluru RA, Kennedy A,. 2001. Therapeutic potential of anti-oxidants and diabetic retinopathy. Expert Opin Investig Drugs 10: 1665-1676.
75. Laaksonen DE, Lindstrom J, Lakka TA, et al., 2005. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes 54: 158-165.
76. Lau BHS, Riesen SK, Truong KP, Lau EW, Rohdewald P, Barreta RA,. 2004. Pycnogenol® as an adjunct in the management of childhood asthma. J Asthma 41: 825-832.
77. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG,. 1997. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 95: 588-593.
78. Li S, Shin HJ, Ding EL, van Dam RM,. 2009. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302: 179-188.
79. Lindstrom J, Absetz P, Hemio K, Peltomaki P, Peltonen M,. 2010. Reducing the risk of type 2 diabetes with nutrition and physical activity-efficacy and implementation of lifestyle interventions in Finland. Public Health Nutr 13: 993-999.
80. Liu X, Wei J, Tan F, Zhou S, Wurthwein G, Rohdewald P,. 2004a. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sci 74: 855-862.
81. Liu X, Wei J, Tan F, Zhou S, Wurthwein G, Rohdewald P,. 2004b. Antidiabetic effect of Pycnogenol French maritime pine bark extract in patients with diabetes type II. Life Sci 75: 2505-2513.
82. Liu X, Zhou HJ, Rohdewald P,. 2004c. French maritime pine bark extract Pycnogenol dose-dependently lowers glucose in type 2 diabetic patients. Diabetes Care 27: 839.
83. McConnaughey MM, McConnaughey JS, Ingenito AJ,. 1999. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol 39: 547-559.
84. NCEP-ATP III. 2001. Executive summary of the Third Report of The National Cholesterol Education Programm (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adultss (Adult Treatment Panel III). JAMA 16: 442-443.
85. Nelson AB, Lau BH, Ide N, Rong Y,. 1998. Pycnogenol inhibits macrophage oxidative burst, lipoprotein oxidation, and hydroxyl radical-induced DNA damage. Drug Dev Ind Pharm 24: 139-144.
86. Niarchos AP, Gulati OP, Carretero OA,. 1977. Effects of propranolol on the development of renovascular hypertension in the rat. Am Heart J 94: 81-86.
87. Nilsen V, Bakke PS, Gallefoss F,. 2011. Effects of lifestyle intervention in persons at risk for type 2 diabetes mellitus-results from a randomised, controlled trial. BMC Public Health 11: 893.
88. Nuzum DS, Gebru TT, Kouzi SA,. 2010 Pycnogenol for chronic venous insufficiency. Am J Health Syst Pharm 68: 1589-1590, 1599-1601.
89. Oliff H, 2009. Scitific and clinical monograph on Pycnogenol. The American Botanical Council.
90. Ozer Sehirli A, Sener G, Ercan F,. 2009. Protective effects of pycnogenol against ischemia reperfusion-induced oxidative renal injury in rats. Ren Fail 31: 690-697.
91. Packer L, Rimbach G, Virgili F,. 1999. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, Pycnogenol. Free Radic Biol Med 27: 704-724.
92. Parveen K, Khan MR, Siddiqui WA,. 2009. Pycnogenol prevents potassium dichromate K2Cr2O7-induced oxidative damage and nephrotoxicity in rats. Chem Biol Interact 181: 343-350.
93. Parveen K, Khan MR, Mujeeb M, Siddiqui WA,. 2010. Protective effects of Pycnogenol on hyperglycemia-induced oxidative damage in the liver of type 2 diabetic rats. Chem Biol Interact 186: 219-227.
94. Peng Q, Wei Z, Lau BH,. 2000. Pycnogenol inhibits tumor necrosis factor-alpha-induced nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci 57: 834-841.
95. Puruhito,. 2000. Pathophysiology of microcirculation in venous disease. Clin Hemorheol Microcirc 23: 239-242.
96. Putter M, Grotemeyer KH, Wurthwein G, et al., 1999. Inhibition of smoking-induced platelet aggregation by aspirin and pycnogenol. Thromb Res 95: 155-161.
97. Rimbach G, Virgili F, Park YC, Packer L,. 1999. Effect of procyanidins from Pinus maritima on glutathione levels in endothelial cells challenged by 3-morpholinosydnonimine or activated macrophages. Redox Rep 4: 171-177.
98. Rohdewald P, 1998. Pycnogenol®. In Flavonoids in Health and Disease, Rice-Evans CA, Packer L, (ed.). Marcel Dekker Inc.: New York, 405-419.
99. Rohdewald P,. 2002. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 40: 158-168.
100. Rong Y, Li L, Shah V, Lau BH,. 1994-1995. Pycnogenol protects vascular endothelial cells from t-butyl hydroperoxide induced oxidant injury. Biotechnol Ther 5: 117-126.
101. Saliou C, Rimbach G, Moini H, et al., 2001. Solar ultraviolet-induced erythema in human skin and nuclear factor-kappa-B-dependent gene expression in keratinocytes are modulated by a French maritime pine bark extract. Free Radic Biol Med 30: 154-160.
102. Schafer A, Hogger P,. 2007. Oligomeric procyanidins of French maritime pine bark extract (Pycnogenol) effectively inhibit alpha-glucosidase. Diabetes Res Clin Pract 77: 41-46.
103. Scheen AJ,. 2003. Pathophysiology of type 2 diabetes. Acta Clin Belg 58: 335-341.
104. Segura J, Ruilope LM,. 2007. Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr 10: 1151-1155.
105. Shreenivas S, Oparil S,. 2007. The role of endothelin-1 in human hypertension. Clin Hemorheol Microcirc 37: 157-178.
106. Steigerwalt R, Belcaro G, Cesarone MR, et al., 2009. Pycnogenol improves microcirculation, retinal edema, and visual acuity in early diabetic retinopathy. J Ocul Pharmacol Ther 25: 537-540.
107. Steinmetz A, Fenselau S, Schrezenmeir J,. 2001. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes 109: S548-S559.
108. Stuard S, Belcaro G, Cesarone MR, et al., 2010. Kidney function in metabolic syndrome may be improved with Pycnogenol(R). Panminerva Med 52: 27-32.
109. Taner G, Aydin S, Aytac Z, Basaran AA, Basaran N,. 2013. Assessment of the cytotoxic, genotoxic, and antigenotoxic potential of Pycnogenol(R) in in vitro mammalian cells. Food Chem Toxicol 61: 203-208.
110. Taner G, Aydin S, Bacanli M, et al., 2014. Modulating effects of pycnogenol(R) on oxidative stress and DNA damage induced by sepsis in rats. Phytother Res 28: 1692-1700.
111. Touyz RM, Schiffrin EL,. 2003. Role of endothelin in human hypertension. Can J Physiol Pharmacol 81: 533-541.
112. United States Pharmacopeial Convention I. 2007. Maritime Pine Extract. In United States Pharmacopoeia-National Formulary.: Rockville, USA; 965-966.
113. US Pharmacopeial Convention. 2011. Maritime pine extract. In United States Pharmacopoeia ed. National Formulary: Rockville, USA; 1196-1197.
114. Vincent HK, Taylor AG,. 2006. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond) 30: 400-418.
115. Virgili F, Kim D, Packer L,. 1998. Procyanidins extracted from pine bark protect alpha-tocopherol in ECV 304 endothelial cells challenged by activated RAW 264.7 macrophages: role of nitric oxide and peroxynitrite. FEBS Lett 431: 315-318.
116. Virgili F, Kobuchi H, Noda Y, Cossins E, Packer L,. 1999. Procyanidins from Pinus maritima bark: Antioxidant activity, effects on the immune system and modulation of nitrogen monoxide metabolism. In Antioxidant Food Supplements in Human Health, Packer L, Hiramatsu M, Yoshikawa T, (eds.). Academic Press: New York, USA; 323-342.
117. Vlek AL, van der Graaf Y, Spiering W, Visseren FL, group Ss. 2008. Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients. J Hum Hypertens 22: 358-365.
118. Vyssoulis GP, Pietri PG, Karpanou EA, et al., 2010. Differential impact of metabolic syndrome on arterial stiffness and wave reflections: focus on distinct definitions. Int J Cardiol 138: 119-125.
119. Watson RR,. 1999. Reduction of cardiovascular disease risk factors by French Maritime Pine Bark Extract. Cardiovasc Rev Rep XX: 326-329.
120. Wei ZH, Peng QL, Lau BHS,. 1997. Pycnogenol enhances endothelial cell antioxidant defenses. Redox Rep 3: 219-224.
121. Weinberger MH,. 1996. Salt sensitivity of blood pressure in humans. Hypertension 27: 481-490.
122. Weisell RC,. 2002. Body mass index as an indicator of obesity. Asia Pac J Clin Nutr 11 (Suppl 8): S681-S684.
123. Wood JM, Gulati N, Forgiarini P, Fuhrer W, Hofbauer KG,. 1985. Effects of a specific and long-acting renin inhibitor in the marmoset. Hypertension 7: 797-803.
124. Wood JM, Gulati N, Michel JB, Hofbauer KG,. 1986a. Two-kidney, one clip renal hypertension in the marmoset. J Hypertens 4: 251-254.
125. Wood JM, Heusser C, Gulati N, Forgiarini P, Hofbauer KG,. 1986b. Monoclonal antibodies against human renin. Blood pressure effects in the marmoset. Hypertension 8: 600-605.
126. Yang YS, Ahn TH, Lee JC, et al., 2008. Protective effects of Pycnogenol on carbon tetrachloride-induced hepatotoxicity in Sprague-Dawley rats. Food Chem Toxicol 46: 380-387.
127. Yang YS, Su YF, Yang HW, Lee YH, Chou JI, Ueng KC,. 2014. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res 28: 1770-1777.
128. Yao SK, Ober JC, Krishnaswami A, et al., 1992. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 86: 1302-1309.
129. Zibadi S, Rohdewald PJ, Park D, Watson RR,. 2008. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. Nutr Res 28: 315-320.
130. Zimmet PZ, Alberti KG, Shaw JE,. 2005. Mainstreaming the metabolic syndrome: a definitive definition. Med J Aust 183: 175-176.